Company news

Delta-Fly Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Update on the Phase 2／3 Clinical Trial of DFP-17729

August 31, 2026

Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax

March 3, 2025

Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax

December 9, 2024

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

December 4, 2024

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

November 26, 2024

Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

November 5, 2024

Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients Begins with Promising Initial Data

October 28, 2024

Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients

September 10, 2024

Delta-Fly Pharma Inc. - Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323

July 4, 2024

Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323

July 3, 2024

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax

April 8, 2024

Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen

March 11, 2024

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

February 7, 2024

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323

February 2, 2024

Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML

January 5, 2024

Delta-Fly Pharma Inc.: Schedule for the Interim Analysis of the Phase 3 study of DFP-10917 in R/R AML

June 30, 2023

Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917

December 7, 2022

Delta-Fly Pharma: Initiated Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927

November 26, 2019

Decks

The 5 newest of 17 decks. Every deck is listed under its year.